Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1980 Feb;34:203–212. doi: 10.1289/ehp.8034203

Tissue organ distribution and behavioral effects of platinum following acute and repeated exposure of the mouse to platinum sulfate.

B A Lown, J B Morganti, C H Stineman, R B D'Agostino, E J Massaro
PMCID: PMC1568532  PMID: 7389684

Abstract

Platinum sulfate was administered intragastrically (IG) to adult male Swiss mice in a single dose at the 7 day LD5 or LD25 level. Control groups received 0.25M H2SO4 (pH 0.85) or 0.14M NaCl. Open field behavior (ambulations, rearings) was measured, and tissue/organ Pt levels determined at 4 hr, or 1, 3, or 7 days post administration. At all times, the LD25 depressed ambulations significantly and rearings marginally. It did not effect exploratory ("hole-in-board") behavior. The LD25 resulted in disproportionately high tissue Pt levels relateive to the LD5. There were significant inverse correlations between behavior and tissue Pt levels for most tissues, but not for brain. In related experiments, adult male mice were subjected to repeated IG administration of Pt(SO4)2 at the LD1 level (one dose every 72 hr for up to 10 doses). Three days after administration of the final dose of each series, open-field and exploratory performance were measured and tissue/organ Pt levels determined. Tissue/organ Pt levels were variable but generally increased with dose number. No Pt was detected in the brain. Activity and explorations were marginally depressed. Only rearings correlated significantly with tissue Pt levels.

Full text

PDF
203

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brubaker P. E., Moran J. P., Bridbord K., Hueter F. G. Noble metals: a toxicological appraisal of potential new environmental contaminants. Environ Health Perspect. 1975 Apr;10:39–56. doi: 10.1289/ehp.751039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cleare M. J., Hughes E. G., Jacoby B., Pepys J. Immediate (type I) allergic responses to platinum compounds. Clin Allergy. 1976 Mar;6(2):183–195. doi: 10.1111/j.1365-2222.1976.tb01897.x. [DOI] [PubMed] [Google Scholar]
  3. Cousins R. J. Metallothionein synthesis and degradation: relationship to cadmium metabolism. Environ Health Perspect. 1979 Feb;28:131–136. doi: 10.1289/ehp.7928131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. DeConti R. C., Toftness B. R., Lange R. C., Creasey W. A. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res. 1973 Jun;33(6):1310–1315. [PubMed] [Google Scholar]
  5. Gessner P. K., Cabana B. E. A study of the interaction of the hypnotic effects and of the toxic effects of chloral hydrate and ethanol. J Pharmacol Exp Ther. 1970 Aug;174(2):247–259. [PubMed] [Google Scholar]
  6. Higby D. J., Wallace H. J., Jr, Holland J. F. Cis-diamminedichloroplatinum (NSC-119875): a phase I study. Cancer Chemother Rep. 1973 Nov-Dec;57(4):459–463. [PubMed] [Google Scholar]
  7. Lange R. C., Spencer R. P., Harder H. C. The antitumor agent cis-Pt(NH 3 ) 2 Cl 2 : distribution studies and dose calculations for 193m Pt and 195m Pt. J Nucl Med. 1973 Apr;14(4):191–195. [PubMed] [Google Scholar]
  8. Leh F. K., Wolf W. Platinum complexes: a new class of antineoplastic agents. J Pharm Sci. 1976 Mar;65(3):315–328. doi: 10.1002/jps.2600650303. [DOI] [PubMed] [Google Scholar]
  9. Levene G. M. Platinum sensitivity. Br J Dermatol. 1971 Dec;85(6):590–593. doi: 10.1111/j.1365-2133.1971.tb14090.x. [DOI] [PubMed] [Google Scholar]
  10. Litterst C. L., Gram T. E., Dedrick R. L., Leroy A. F., Guarino A. M. Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs. Cancer Res. 1976 Jul;36(7 Pt 1):2340–2344. [PubMed] [Google Scholar]
  11. Moore W., Jr, Hysell D., Crocker W., Stara J. Biological fate of a single administration of 191Pt in rats following different routes of exposure. Environ Res. 1975 Apr;9(2):152–158. doi: 10.1016/0013-9351(75)90059-6. [DOI] [PubMed] [Google Scholar]
  12. Rossof A. H., Slayton R. E., Perlia C. P. Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP). Cancer. 1972 Dec;30(6):1451–1456. doi: 10.1002/1097-0142(197212)30:6<1451::aid-cncr2820300606>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  13. Schaeppi U., Heyman I. A., Fleischman R. W., Rosenkrantz H., Ilievski V., Phelan R., Cooney D. A., Davis R. D. cis-Dichlorodiammineplatinum(II) (NSC-119 875): preclinical toxicologic evaluation of intravenous injection in dogs, monkeys and mice. Toxicol Appl Pharmacol. 1973 Jun;25(2):230–241. doi: 10.1016/s0041-008x(73)80009-2. [DOI] [PubMed] [Google Scholar]
  14. Stadnicki S. W., Fleischman R. W., Schaeppi U., Merriam P. Cis-dichlorodiammineplatinum (II) (NSC-119875): hearing loss and other toxic effects in rhesus monkeys. Cancer Chemother Rep. 1975 May-Jun;59(3):467–480. [PubMed] [Google Scholar]
  15. Talley R. W., O'Bryan R. M., Gutterman J. U., Brownlee R. W., McCredie K. B. Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)--phase I clinical study. Cancer Chemother Rep. 1973 Nov-Dec;57(4):465–471. [PubMed] [Google Scholar]
  16. Tillery J. B., Johnson D. E. Determination of platinum, palladium, and lead in biological samples by atomic absorption spectrophotometry. Environ Health Perspect. 1975 Dec;12:19–26. doi: 10.1289/ehp.751219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Waters M. D., Vaughan T. O., Abernethy D. J., Garland H. R., Cox C. C., Coffin D. L. Toxicity of platinum (IV) salts for cells of pulmonary origin. Environ Health Perspect. 1975 Dec;12:45–56. doi: 10.1289/ehp.751245. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES